Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Vernalis plc
Vernalis plc
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Three milestones in Servier and Vernalis oncology drug discovery collaboration
Two research milestones and one clinical milestone, triggering a total payment of €2m to Vernalis
Research & Development
Servier and Vernalis announce three milestones in their oncology drug discovery collaboration
Two research milestones and one clinical milestone reached, triggering a total payment of €2 million to Vernalis
Research & Development
Vernalis and Servier enter drug discovery collaboration
Vernalis and Servier will enter into a new two-year oncology drug discovery collaboration on an undisclosed target
Regulatory
FDA accepts CCP-08 NDA for full review
PDUFA date of 4 August 2017
Research & Development
Sandford Sommer joins Vernalis as President & Chief Operating Officer
Prior to joining the UK firm Sommer spent 24 years at AstraZeneca
Research & Development
Pharmaceutical industry rewarded in Queen\'s Awards for Enterprise 2014
Four companies honoured for International Trade and two for Innovation
Subscribe now